Cabaletta Bio presents first rese-cel data without preconditioning at ESGCT 2025

Cabaletta Bio, Inc.

Rese-cel without preconditioning achieved complete B cell depletion in two of three PV patients, with rapid autoantibody reduction and near-complete symptom resolution.
PDAI activity scores improved from baseline to latest follow-up: Patient 1 (24 to 10 at 4 mo), Patient 2 (83 to 3 at 3 mo), Patient 3 (22 to 2 at 1 mo).
All three patients remained off immunomodulators since infusion and are off or tapering steroids as of the September 11, 2025 data cut-off.
CAR T cell expansion kinetics without preconditioning were similar to those observed across 30+ patients dosed with preconditioning in other RESET trials.
No ICANS was reported; one patient had transient grade 1 CRS, and another required steroids for a disease flare that later tapered below baseline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.